{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:10:01Z","timestamp":1770567001500,"version":"3.49.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11033-021-06863-3","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:02:59Z","timestamp":1636120979000},"page":"717-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Resistance to endocrine therapy in HR\u2009+\u2009and\/or HER2\u2009+\u2009breast cancer: the most promising predictive biomarkers"],"prefix":"10.1007","volume":"49","author":[{"given":"Fl\u00e1via","family":"Miranda","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-6642","authenticated-orcid":false,"given":"Hugo","family":"Prazeres","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-8939","authenticated-orcid":false,"given":"Fernando","family":"Mendes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-8992","authenticated-orcid":false,"given":"Diana","family":"Martins","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-8681","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"6863_CR1","unstructured":"Globocan. Estimated number of new cases in 2018, Worldwide, all cancers, Females, all ages [Internet]. Vol. 849, Cancer Today. 2018. p. 2018. Available from: http:\/\/gco.iarc.fr\/today\/online-analysis-pie?v=2018&mode=cancer&mode_population=continents&population=900&populations=710&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_"},{"key":"6863_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amsu.2019.11.021","volume":"49","author":"FK Al-thoubaity","year":"2020","unstructured":"Al-thoubaity FK (2020) Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg 49:44\u201348","journal-title":"Ann Med Surg"},{"key":"6863_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P et al (2019) Breast cancer. Nat Rev Dis Prim 5:1\u201331","journal-title":"Nat Rev Dis Prim"},{"key":"6863_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/annonc\/mds326","volume":"23","author":"G Viale","year":"2012","unstructured":"Viale G (2012) The current state of breast cancer classification. Ann Oncol 23:207\u2013210","journal-title":"Ann Oncol"},{"key":"6863_CR5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752","journal-title":"Nature"},{"key":"6863_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-018-5023-4","volume":"173","author":"M Szostakowska","year":"2019","unstructured":"Szostakowska M, Tr\u0119bi\u0144ska-Stryjewska A, Grzybowska EA, Fabisiewicz A (2019) Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat 173:489\u2013497","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR7","first-page":"1","volume":"19","author":"T Reinert","year":"2018","unstructured":"Reinert T, Gon\u00e7alves R, Bines J (2018) Implications of ESR1 mutations in hormone receptor-positive breast cancer. Curr Treat Options Oncol 19:1\u201313","journal-title":"Curr Treat Options Oncol"},{"key":"6863_CR8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/1758834017728928","volume":"9","author":"T Reinert","year":"2017","unstructured":"Reinert T, Barrios CH (2017) Overall survival and progression-free survival with endocrine therapy for hormone breast cancer\u202f: review. Ther Adv Med Oncol 9:693\u2013709","journal-title":"Ther Adv Med Oncol"},{"key":"6863_CR9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","volume":"7","author":"T Reinert","year":"2015","unstructured":"Reinert T, Barrios CH (2015) Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol 7:304\u2013320","journal-title":"Ther Adv Med Oncol"},{"key":"6863_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2016","unstructured":"Hsu JL, Hung M-C (2016) The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev 35:575\u2013588","journal-title":"Cancer Metastasis Rev"},{"key":"6863_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","volume":"139","author":"C Vernieri","year":"2019","unstructured":"Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS et al (2019) Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 139:53\u201366","journal-title":"Crit Rev Oncol Hematol"},{"key":"6863_CR12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","volume":"418","author":"R Clarke","year":"2015","unstructured":"Clarke R, Tyson JJ, Dixon JM (2015) Endocrine resistance in breast cancer\u2014an overview and update. Mol Cell Endocrinol 418:220\u2013234","journal-title":"Mol Cell Endocrinol"},{"key":"6863_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2019.00573","volume":"10","author":"MM Haque","year":"2019","unstructured":"Haque MM, Desai KV (2019) Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne) 10:1\u20137","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6863_CR14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-017-4612-y","volume":"168","author":"H Fang","year":"2018","unstructured":"Fang H, Huang D, Yang F, Guan X (2018) Potential biomarkers of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Res Treat 168:287\u2013297","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semcancer.2017.08.010","volume":"52","author":"A Nicolini","year":"2018","unstructured":"Nicolini A, Ferrari P, Duffy MJ (2018) Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol 52:56\u201373","journal-title":"Semin Cancer Biol"},{"issue":"7757","key":"6863_CR16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N et al (2019) Genomic characterization of metastatic breast cancers. Nature 569(7757):560\u2013564","journal-title":"Nature"},{"key":"6863_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-016-0779-0","volume":"18","author":"C Selli","year":"2016","unstructured":"Selli C, Dixon JM, Sims AH (2016) Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res 18:1\u201310","journal-title":"Breast Cancer Res"},{"key":"6863_CR18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H et al (2015) Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature 518:240\u2013244","journal-title":"Nature"},{"key":"6863_CR19","first-page":"1","volume":"5","author":"JT Lei","year":"2019","unstructured":"Lei JT, Gou X, Seker S, Ellis MJ (2019) ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat 5:1\u201316","journal-title":"J Cancer Metastasis Treat"},{"key":"6863_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1178-0","volume":"22","author":"A Zundelevich","year":"2020","unstructured":"Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M et al (2020) ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res 22:1\u201311","journal-title":"Breast Cancer Res"},{"key":"6863_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2019.00245","volume":"10","author":"A Rani","year":"2019","unstructured":"Rani A, Stebbing J, Giamas G, Murphy J (2019) Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne) 10:1\u201332","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6863_CR22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37:496\u2013513","journal-title":"Cancer Cell"},{"key":"6863_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA (2021) ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23:1\u201315","journal-title":"Breast Cancer Res"},{"key":"6863_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","author":"SW Fanning","year":"2016","unstructured":"Fanning SW, Mayne CG, Dharmarajan V et al (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. https:\/\/doi.org\/10.7554\/eLife.12792","journal-title":"Elife"},{"key":"6863_CR25","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.18632\/aging.101690","volume":"10","author":"M Fiorillo","year":"2018","unstructured":"Fiorillo M, Sanchez-Alvarez R, Sotgia F, Lisanti MP (2018) The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI\/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy. Aging (Albany NY) 10:4000\u20134023","journal-title":"Aging (Albany NY)"},{"key":"6863_CR26","doi-asserted-by":"crossref","first-page":"52142","DOI":"10.18632\/oncotarget.18479","volume":"8","author":"T Takeshita","year":"2017","unstructured":"Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K et al (2017) Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget 8:52142\u201352155","journal-title":"Oncotarget"},{"key":"6863_CR27","doi-asserted-by":"crossref","first-page":"74448","DOI":"10.18632\/oncotarget.12950","volume":"7","author":"F Clatot","year":"2016","unstructured":"Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C et al (2016) Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget 7:74448\u201374459","journal-title":"Oncotarget"},{"key":"6863_CR28","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","volume":"10","author":"K Zhang","year":"2018","unstructured":"Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G et al (2018) Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis. Cancer Manag Res 10:2573\u20132580","journal-title":"Cancer Manag Res"},{"key":"6863_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11121894","volume":"11","author":"I De Santo","year":"2019","unstructured":"De Santo I, McCartney A, Migliaccio I, Di Leo A, Malorni L (2019) The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy. Cancers (Basel) 11:1\u201315","journal-title":"Cancers (Basel)"},{"key":"6863_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-0968-0","volume":"20","author":"V Allouchery","year":"2018","unstructured":"Allouchery V, Beaussire L, Perdrix A, Sefrioui D, Augusto L, Guillemet C et al (2018) Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res 20:1\u20135","journal-title":"Breast Cancer Res"},{"key":"6863_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-murillas I, Cutts RJ, Tarazona N, Fenwick K et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7:1\u201319","journal-title":"Sci Transl Med"},{"key":"6863_CR32","doi-asserted-by":"crossref","first-page":"66901","DOI":"10.18632\/oncotarget.11383","volume":"8","author":"R Gyanchandani","year":"2017","unstructured":"Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, Knapick BA, Oesterreich S et al (2017) Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget 8:66901\u201366911","journal-title":"Oncotarget"},{"key":"6863_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X et al (2018) Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 9:1\u201310","journal-title":"Nat Commun"},{"key":"6863_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-020-0871-6","volume":"22","author":"J Xi","year":"2020","unstructured":"Xi J, Ma CX (2020) Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on a CDK4\/6 inhibitor? Curr Oncol Rep 22:1\u201312","journal-title":"Curr Oncol Rep"},{"key":"6863_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11579","volume":"7","author":"JM Spoerke","year":"2016","unstructured":"Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H et al (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:1\u201310","journal-title":"Nat Commun"},{"key":"6863_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2019.06.017","volume":"20","author":"S Sammons","year":"2020","unstructured":"Sammons S, Shastry M, Dent S, Anders C, Hamilton E (2020) Practical treatment strategies and future directions after progression while receiving CDK4\/6 inhibition and endocrine therapy in advanced HR+\/HER2\u2014breast cancer. Clin Breast Cancer 20:1\u201311","journal-title":"Clin Breast Cancer"},{"key":"6863_CR37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1634\/theoncologist.2017-0423","volume":"5","author":"AM Brufsky","year":"2018","unstructured":"Brufsky AM, Dickler MN (2018) Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist 5:528\u2013539","journal-title":"Oncologist"},{"key":"6863_CR38","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD7-05","author":"K Jhaveri","year":"2020","unstructured":"Jhaveri K, Winer EP, Lim E, Fidalgo JA, Bellet M, Mayer IA, Boni V, Patel JM, Bardia A, Garcia JM, Kabos P, Gates M, Chen Y, Fredrickson J, Wang X, Friedman LS, Loi S (2020) A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-PD7-05","journal-title":"Cancer Res"},{"key":"6863_CR39","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1158\/1078-0432.CCR-18-1569","volume":"24","author":"C Paoletti","year":"2018","unstructured":"Paoletti C, Dolce EM, Schiavon G, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Baird R, Hayes DF (2018) Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 Oral SERD phase I trial. Clin Cancer Res 24:5860\u201372","journal-title":"Clin Cancer Res"},{"key":"6863_CR40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2174\/156800961508151001101742","volume":"15","author":"O Menyh\u00e1rt","year":"2015","unstructured":"Menyh\u00e1rt O, Santarpia L, Gy\u0151rffy B (2015) A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer. Curr Cancer Drug Targets 15:665\u2013683","journal-title":"Curr Cancer Drug Targets"},{"key":"6863_CR41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B et al (2020) Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res 26:608\u2013622","journal-title":"Clin Cancer Res"},{"key":"6863_CR42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34:427\u2013438","journal-title":"Cancer Cell"},{"key":"6863_CR43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdy497","volume":"30","author":"ES Sokol","year":"2019","unstructured":"Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM et al (2019) Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol 30:115\u2013123","journal-title":"Ann Oncol"},{"key":"6863_CR44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13:417\u2013430","journal-title":"Nat Rev Clin Oncol"},{"key":"6863_CR45","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389:2415\u20132429","journal-title":"Lancet"},{"key":"6863_CR46","first-page":"21","volume":"10","author":"M Luque-Cabal","year":"2016","unstructured":"Luque-Cabal M, Garc\u00eda-Teijido P, Fern\u00e1ndez-P\u00e9rez Y, S\u00e1nchez-Lorenzo L, Palacio-V\u00e1zquez I (2016) Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol 10:21\u201330","journal-title":"Clin Med Insights Oncol"},{"key":"6863_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919833519","volume":"11","author":"S Pernas","year":"2019","unstructured":"Pernas S, Tolaney SM (2019) HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 11:1\u201316","journal-title":"Ther Adv Med Oncol"},{"key":"6863_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/annonc\/mdz281","volume":"30","author":"N Vasan","year":"2019","unstructured":"Vasan N, Toska E, Scaltriti M (2019) Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol 30:3\u201311","journal-title":"Ann Oncol"},{"key":"6863_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2018.1417384","volume":"27","author":"NM Keegan","year":"2018","unstructured":"Keegan NM, Gleeson JP, Hennessy BT, Morris PG (2018) PI3K inhibition to overcome endocrine resistance in breast cancer. Expert Opin Investig Drugs 27:1\u201315","journal-title":"Expert Opin Investig Drugs"},{"key":"6863_CR50","first-page":"1","volume":"12","author":"D Collins","year":"2017","unstructured":"Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Weisser M et al (2017) Direct estrogen receptor (ER)\/HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER + breast cancer. PLoS ONE 12:1\u201316","journal-title":"PLoS ONE"},{"key":"6863_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-012-2067-8","volume":"135","author":"R Nahta","year":"2012","unstructured":"Nahta R, Regan RMO, Crosstalk T\u00c1 (2012) Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 135:39\u201348","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1634\/theoncologist.2018-0314","volume":"24","author":"VG Kaklamani","year":"2019","unstructured":"Kaklamani VG, Richardson AL, Arteaga CL (2019) Exploring biomarkers of phosphoinositide 3-kinase pathway activation in the treatment of hormone receptor positive, human epidermal growth receptor 2 negative advanced breast cancer. Oncologist 24:305\u2013312","journal-title":"Oncologist"},{"key":"6863_CR53","first-page":"1","volume":"8","author":"U Testa","year":"2020","unstructured":"Testa U, Castelli G, Pelosi E (2020) Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci 8:1\u2013103","journal-title":"Med Sci"},{"key":"6863_CR54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"B Verret","year":"2019","unstructured":"Verret B, Cortes J, Bachelot T, Andre F, Arnedos M (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol Off J Eur Soc Med Oncol 30:12\u201320","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"6863_CR55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000481657","volume":"12","author":"F Schettini","year":"2017","unstructured":"Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M (2017) PI3K\/mTOR Inhibitors in the treatment of luminal breast cancer. Why When and to whom? Breast Care 12:290\u20134","journal-title":"Breast Care"},{"key":"6863_CR56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","volume":"25","author":"K Araki","year":"2018","unstructured":"Araki K, Miyoshi Y (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 25:392\u2013401","journal-title":"Breast Cancer"},{"key":"6863_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01328-0","volume":"22","author":"CT van Geelen","year":"2020","unstructured":"van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng C-F, Ko Y-A et al (2020) Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res 22:1\u201313","journal-title":"Breast Cancer Res"},{"key":"6863_CR58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-014-3080-x","volume":"147","author":"LM Arthur","year":"2014","unstructured":"Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR et al (2014) Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast Cancer Res Treat 147:211\u2013219","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-019-05349-y","volume":"177","author":"W Jacot","year":"2019","unstructured":"Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N et al (2019) PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Res Treat 177:659\u2013667","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdz280","volume":"30","author":"M Brand\u00e3o","year":"2019","unstructured":"Brand\u00e3o M, Caparica R, Eiger D, de Azambuja E (2019) Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol 30:27\u201342","journal-title":"Ann Oncol"},{"key":"6863_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12907-015-0020-6","volume":"15","author":"R Arsenic","year":"2015","unstructured":"Arsenic R, Treue D, Lehmann A, Hummel M, Dietel M, Denkert C et al (2015) Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol 15:1\u20139","journal-title":"BMC Clin Pathol"},{"key":"6863_CR62","first-page":"4252","volume":"130","author":"MR Paul","year":"2020","unstructured":"Paul MR, Pan T, Pant DK, Shih NN, Chen Y, Harvey KL et al (2020) Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 130:4252\u20134265","journal-title":"J Clin Invest"},{"key":"6863_CR63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P et al (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534:55\u201362","journal-title":"Nature"},{"key":"6863_CR64","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41416-018-0221-8","volume":"119","author":"DT Kruger","year":"2018","unstructured":"Kruger DT, Beelen KJ, Opdam M, Sanders J, van der Noort V, Boven E et al (2018) Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. Br J Cancer 119:832\u2013839","journal-title":"Br J Cancer"},{"key":"6863_CR65","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2015.63.9161","volume":"34","author":"F Andr\u00e9","year":"2016","unstructured":"Andr\u00e9 F, Hurvitz S, Fasolo A, Tseng L-M, Jerusalem G, Wilks S et al (2016) Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2\u2013overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34:2115\u20132124","journal-title":"J Clin Oncol"},{"key":"6863_CR66","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-16-0591","volume":"23","author":"RC Jankowitz","year":"2017","unstructured":"Jankowitz RC, Oesterreich S, Lee AV, Davidson NE (2017) New strategies in metastatic hormone receptor-positive breast cancer: searching for biomarkers to tailor endocrine and other targeted therapies. Clin Cancer Res 23:1126\u20131131","journal-title":"Clin Cancer Res"},{"key":"6863_CR67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N et al (2020) Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 31:377\u2013386","journal-title":"Ann Oncol"},{"key":"6863_CR68","unstructured":"FDA approves first PI3K inhibitor for breast cancer | FDA [Internet]. [cited 2020 Sep 8]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-pi3k-inhibitor-breast-cancer"},{"key":"6863_CR69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10408363.2019.1670615","volume":"57","author":"E Tzanikou","year":"2020","unstructured":"Tzanikou E, Lianidou E (2020) The potential of ctDNA analysis in breast cancer. Crit Rev Clin Lab Sci 57:54\u201372","journal-title":"Crit Rev Clin Lab Sci"},{"key":"6863_CR70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","volume":"191","author":"F Lynce","year":"2018","unstructured":"Lynce F, Shajahan-Haq AN, Swain SM (2018) CDK4\/6 inhibitors in breast cancer therapy: current practice and future opportunities. Pharmacol Ther 191:65\u201373","journal-title":"Pharmacol Ther"},{"key":"6863_CR71","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S, Masuda N et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas. Lancet Oncol 17:425\u2013439","journal-title":"Lancet Oncol"},{"key":"6863_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00666","volume":"9","author":"A McCartney","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F et al (2019) Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol 9:1\u20138","journal-title":"Front Oncol"},{"key":"6863_CR73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Ye W, Ly A, Hosono Y, Murchi E, Walmsley CS et al (2020) Pten loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer. Cancer Discov 10:72\u201385","journal-title":"Cancer Discov"},{"key":"6863_CR74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","volume":"1","author":"P Razavi","year":"2020","unstructured":"Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH et al (2020) Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer 1:382\u2013393","journal-title":"Nat Cancer"},{"key":"6863_CR75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.matbio.2013.09.002","volume":"35","author":"SS Skandalis","year":"2014","unstructured":"Skandalis SS, Afratis N, Smirlaki G, Nikitovic D, Theocharis AD, Tzanakakis GN et al (2014) Cross-talk between estradiol receptor and EGFR\/IGF-IR signaling pathways in estrogen-responsive breast cancers\u202f: Focus on the role and impact of proteoglycans. Matrix Biol 35:182\u2013193","journal-title":"Matrix Biol"},{"key":"6863_CR76","first-page":"1","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zheng X, Zheng Y et al (2021) Extracellular matrix\u202f: emerging roles and potential therapeutic targets for breast cancer. Front Oncol 11:1\u201314","journal-title":"Front Oncol"},{"key":"6863_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10163498","volume":"10","author":"T Saha","year":"2021","unstructured":"Saha T, Solomon J, Samson A, Gil-Henn H (2021) Invasion and metastasis as a central hallmark of breast cancer. J Clin Med 10:1\u201312","journal-title":"J Clin Med"},{"key":"6863_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep40138","volume":"7","author":"NA Afratis","year":"2017","unstructured":"Afratis NA, Bouris P, Skandalis SS et al (2017) IGF-IR cooperates with ER\u03b1 to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules. Sci Rep 7:1\u201312","journal-title":"Sci Rep"},{"key":"6863_CR79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.matbio.2015.02.008","volume":"43","author":"P Bouris","year":"2015","unstructured":"Bouris P, Skandalis SS, Piperigkou Z et al (2015) Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol 43:42\u201360","journal-title":"Matrix Biol"},{"key":"6863_CR80","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/s41388-020-1194-7","volume":"36","author":"C Chen","year":"2020","unstructured":"Chen C, Gupta P, Parashar D et al (2020) ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R\/STAT3 signaling axis. Oncogene 36:2921\u20132933","journal-title":"Oncogene"},{"key":"6863_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2021.641449","volume":"9","author":"A Ianza","year":"2021","unstructured":"Ianza A, Sirico M, Bernocchi O et al (2021) Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer. Front Cell Development Biol 9:1\u20139","journal-title":"Front Cell Development Biol"},{"key":"6863_CR82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-014-0177-3","volume":"33","author":"JC Bendell","year":"2015","unstructured":"Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C et al (2015) A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Investig New Drugs 33:187\u2013193","journal-title":"Investig New Drugs"},{"key":"6863_CR83","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-018-0574-0","volume":"36","author":"P Barata","year":"2018","unstructured":"Barata P, Cooney M, Tyler A, Wright J, Dreicer R, Garcia JA (2018) A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Investig New Drugs 36:451\u2013457","journal-title":"Investig New Drugs"},{"key":"6863_CR84","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-19-1069","volume":"26","author":"M von Mehren","year":"2020","unstructured":"von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ et al (2020) Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study. Clin Cancer Res 26:1837\u20131845","journal-title":"Clin Cancer Res"},{"key":"6863_CR85","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","volume":"26","author":"N Portman","year":"2019","unstructured":"Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE (2019) Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer 26:R15-30","journal-title":"Endocr Relat Cancer"},{"key":"6863_CR86","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.7150\/jca.32628","volume":"10","author":"Y Niu","year":"2019","unstructured":"Niu Y, Xu J, Sun T (2019) Cyclin-dependent kinases 4\/6 inhibitors in breast cancer: current status, resistance, and combination strategies. J Cancer 10:5504\u20135517","journal-title":"J Cancer"},{"key":"6863_CR87","first-page":"216","volume":"32","author":"M Shah","year":"2018","unstructured":"Shah M, Nunes MR, Stearns V (2018) CDK4\/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park) 32:216\u2013222","journal-title":"Oncology (Williston Park)"},{"key":"6863_CR88","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Spring L, O\u2019Shaughnessy J, Lacroix L, Bailleux C, Scott V et al (2018) Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 29:640\u2013645","journal-title":"Ann Oncol"},{"key":"6863_CR89","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1038\/onc.2016.32","volume":"35","author":"J Johnson","year":"2016","unstructured":"Johnson J, Thijssen B, Mcdermott U, Garnett M, Lodewyk FA (2016) Targeting the RB-E2F pathway in breast cancer. Oncogene 35:4829\u20134835","journal-title":"Oncogene"},{"key":"6863_CR90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K et al (2018) The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov 8:1390\u20131403","journal-title":"Cancer Discov"},{"key":"6863_CR91","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C et al (2018) Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway Zhiqiang. Cancer Cell 34:893\u2013905","journal-title":"Cancer Cell"},{"key":"6863_CR92","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-19-3271","volume":"26","author":"A McCartney","year":"2020","unstructured":"McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E et al (2020) Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial. Clin Cancer Res 26:2131\u20132139","journal-title":"Clin Cancer Res"},{"key":"6863_CR93","doi-asserted-by":"crossref","first-page":"16389","DOI":"10.18632\/oncotarget.24700","volume":"9","author":"M Bonechi","year":"2018","unstructured":"Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neum\u00fcller M et al (2018) Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget 9:16389\u201316399","journal-title":"Oncotarget"},{"key":"6863_CR94","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A et al (2017) NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 23:4055\u20134065","journal-title":"Clin Cancer Res"},{"key":"6863_CR95","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S et al (2019) Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol 37:1169\u20131178","journal-title":"J Clin Oncol"},{"key":"6863_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-018-0092-4","volume":"4","author":"C Guarducci","year":"2018","unstructured":"Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D et al (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer. 4:1\u201310","journal-title":"npj Breast Cancer."},{"key":"6863_CR97","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.2147\/CMAR.S250632","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zhang Y, Pi H, Sheng Y (2020) Current therapeutic progress of CDK4\/6 inhibitors in breast cancer. Cancer Manag Res 12:3477\u20133487","journal-title":"Cancer Manag Res"},{"key":"6863_CR98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-017-0913-7","volume":"19","author":"N Bagegni","year":"2017","unstructured":"Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW et al (2017) Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res 19:1\u201311","journal-title":"Breast Cancer Res"},{"key":"6863_CR99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2019.04.002","volume":"114","author":"A McCartney","year":"2019","unstructured":"McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I et al (2019) Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor\u2013positive metastatic breast cancer: analysis of the randomised phase III evaluation of faslodex versus exemestane clinical trial (EFECT). Eur J Cancer 114:55\u201366","journal-title":"Eur J Cancer"},{"key":"6863_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9768183","volume":"2016","author":"R Saba","year":"2016","unstructured":"Saba R, Alsayed A, Zacny J, Dudek AZ (2016) The role of forkhead box protein M1 in breast cancer progression and resistance to therapy. Int J Breast Cancer 2016:1\u20139","journal-title":"Int J Breast Cancer"},{"key":"6863_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2013-14-1-r6","volume":"14","author":"DA Sanders","year":"2013","unstructured":"Sanders DA, Ross-Innes C, Beraldi D et al (2013) Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol 14:1\u201316","journal-title":"Genome Biol"},{"key":"6863_CR102","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/onc.2010.47","volume":"29","author":"J Millour","year":"2010","unstructured":"Millour J, Constantinidou D, Stavropoulou AV, Wilson MSC et al (2010) FOXM1 is a transcriptional target of ER\u03b1 and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 29:2983\u20132995","journal-title":"Oncogene"},{"key":"6863_CR103","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3346\/jkms.2015.30.4.390","volume":"30","author":"H Ahn","year":"2015","unstructured":"Ahn H, Sim J, Abdul R et al (2015) Increased expression of forkhead Box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor- positive breast cancer. J Korean Med Sci 30:390\u2013397","journal-title":"J Korean Med Sci"},{"key":"6863_CR104","doi-asserted-by":"crossref","first-page":"25167","DOI":"10.1074\/jbc.M603906200","volume":"281","author":"PA Madureira","year":"2006","unstructured":"Madureira PA, Varshochi R, Constantinidou D et al (2006) The forkhead box M1 protein regulates the transcription of the estrogen receptor \u03b1 in breast cancer cells. J Biol Chem 281:25167\u201325176","journal-title":"J Biol Chem"},{"key":"6863_CR105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-014-0436-4","volume":"16","author":"A Bergamaschi","year":"2014","unstructured":"Bergamaschi A, Madak-Erdogan Z, Kim YJ et al (2014) The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res 16:1\u201318","journal-title":"Breast Cancer Res"},{"key":"6863_CR106","first-page":"842","volume":"9","author":"XF Lu","year":"2015","unstructured":"Lu XF, De Zeng, Liang W-Q et al (2015) FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget 9:842\u2013852","journal-title":"Oncotarget"},{"key":"6863_CR107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/onc.2011.223","volume":"31","author":"A Bergamaschi","year":"2012","unstructured":"Bergamaschi A, Katzenellenbogen BS (2012) Tamoxifen down-regulation of miR-451 increases 14-3-3\u03b6 and promotes breast cancer cell survival and endocrine resistance. Oncogene 31:39\u201347","journal-title":"Oncogene"},{"key":"6863_CR108","first-page":"1654","volume":"7","author":"S Joshi","year":"2017","unstructured":"Joshi S, Yang J, Wang Q, Li P, Wang H et al (2017) 14-3-3\u03b6 loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. Am J Res 7:1654\u20131664","journal-title":"Am J Res"},{"key":"6863_CR109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2913","volume":"13","author":"A Bergamaschi","year":"2011","unstructured":"Bergamaschi A, Christensen BL, Katzenellenbogen BS (2011) Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3\u03b6, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 13:1\u201314","journal-title":"Breast Cancer Res"},{"key":"6863_CR110","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/0008-5472.CAN-19-3717","volume":"80","author":"D Parashar","year":"2020","unstructured":"Parashar D, Nair B, Geethadevi A et al (2020) Peritoneal spread of ovarian cancer harbors therapeutic vulnerabilities regulated by FOXM1 and EGFR\/ERBB2 signaling. Cancer Res 80:5554\u20135568","journal-title":"Cancer Res"},{"key":"6863_CR111","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.18632\/oncotarget.2135","volume":"5","author":"G Li","year":"2014","unstructured":"Li G, Zhao L, Li W, Fan K, Qian W (2014) Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 5:8317\u20138329","journal-title":"Oncotarget"},{"key":"6863_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0416-2","volume":"13","author":"A Sonnenblick","year":"2015","unstructured":"Sonnenblick A, Broh\u00e9e S, Fumagalli D, Vincent D, Venet D, Ignatiadis M et al (2015) Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med 13:1\u201310","journal-title":"BMC Med"},{"key":"6863_CR113","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/ERC-11-0326","volume":"4","author":"NR West","year":"2012","unstructured":"West NR, Murphy LC, Watson PH (2012) Oncostatin M suppresses oestrogen receptor- a expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer 4:181\u2013195","journal-title":"Endocr Relat Cancer"},{"key":"6863_CR114","first-page":"1","volume":"92","author":"D Canatan","year":"2021","unstructured":"Canatan D, Y\u0131lmaz \u00d6, S\u00f6nmez Y, \u00c7im A, Co\u015fkun H\u015e, G\u00f6ksu SS et al (2021) Circulating microRNAs as potential non-invasive biomarkers for breast cancer detection. Acta Biomed 92:1\u20137","journal-title":"Acta Biomed"},{"key":"6863_CR115","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.celrep.2019.11.085","volume":"29","author":"D Parashar","year":"2019","unstructured":"Parashar D, Geethadevi A, Aure MR, Mills GB, Pradeep S (2019) miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep 29:4389\u20134406","journal-title":"Cell Rep"},{"key":"6863_CR116","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","volume":"15","author":"P Chaluvally-raghavan","year":"2016","unstructured":"Chaluvally-raghavan P, Jin K, Pradeep S, George A, Sood AK, Mills GB et al (2016) Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian. Cell Rep 15:1493\u20131504","journal-title":"Cell Rep"},{"key":"6863_CR117","first-page":"1","volume":"114","author":"X Ji","year":"2019","unstructured":"Ji X, Lu Y, Tian H, Meng X et al (2019) Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother 114:1\u20139","journal-title":"Biomed Pharmacother"},{"key":"6863_CR118","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li Y-J et al (2018) JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 27:136\u2013150","journal-title":"Cell Metab"},{"key":"6863_CR119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-019-0473-9","volume":"18","author":"J Ma","year":"2020","unstructured":"Ma J, Qin L, Li X (2020) Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal 18:1\u201313","journal-title":"Cell Commun Signal"},{"key":"6863_CR120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13046-018-0999-5","volume":"38","author":"JJ Qin","year":"2019","unstructured":"Qin JJ, Yan L, Zhang J, Zhang WD (2019) STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res 38:16","journal-title":"J Exp Clin Cancer Res"},{"key":"6863_CR121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02179-1","volume":"21","author":"Z Kohandel","year":"2021","unstructured":"Kohandel Z, Farkhondeh T, Aschner M, Mohammad A, Shahri P (2021) STAT3 pathway as a molecular target for resveratrol in breast cancer treatment. Cancer Cell Int 21:1\u20139","journal-title":"Cancer Cell Int"},{"issue":"24","key":"6863_CR122","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","volume":"15","author":"PR Pohlmann","year":"2009","unstructured":"Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to trastuzumab in breast cancer. Clin Cancer Res 15(24):7479\u20137491","journal-title":"Clin Cancer Res"},{"key":"6863_CR123","first-page":"1","volume":"2","author":"T Vu","year":"2012","unstructured":"Vu T, Claret FX (2012) Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2:1\u20137","journal-title":"Front Oncol"},{"key":"6863_CR124","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-012-2082-9","volume":"134","author":"AC Chen","year":"2012","unstructured":"Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC et al (2012) Upregulation of mucin4 in ER-positive\/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2- targeted therapies. Breast Cancer Res Treat 134:583\u2013593","journal-title":"Breast Cancer Res Treat"},{"key":"6863_CR125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.10410","volume":"99","author":"SA Price-Schiavi","year":"2002","unstructured":"Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99:783\u2013791","journal-title":"Int J Cancer"},{"key":"6863_CR126","first-page":"21","volume":"10","author":"M Luque-Cabal","year":"2016","unstructured":"Luque-Cabal M, Garc\u00eda-Teijido P, Fern\u00e1ndez-P\u00e9rex Y et al (2016) Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clinical Medicine Insights: Oncology 10:21\u201330","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"6863_CR127","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","volume":"7","author":"DM Gagliato","year":"2016","unstructured":"Gagliato DM, Jardim DLF et al (2016) Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 7:64431\u201364446","journal-title":"Oncotarget"},{"key":"6863_CR128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F et al (2006) Trastuzumab-based treatment of HER2-positive breast cancer\u202f: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259\u2013267","journal-title":"Br J Cancer"},{"key":"6863_CR129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3039","volume":"13","author":"TW Miller","year":"2011","unstructured":"Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:1\u201312","journal-title":"Breast Cancer Res"},{"key":"6863_CR130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12282-015-0617-8","volume":"23","author":"F Sato","year":"2016","unstructured":"Sato F, Saji S, Toi M (2016) Genomic tumor evolution of breast cancer. Breast Cancer 23:4\u201311","journal-title":"Breast Cancer"},{"key":"6863_CR131","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N et al (2019) Genomic characterization of metastatic breast cancers. Nature 569:560\u2013564","journal-title":"Nature"},{"key":"6863_CR132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317731511","volume":"39","author":"F Reinhardt","year":"2017","unstructured":"Reinhardt F, Franken A, Fehm T, Neubauer H (2017) Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: a potential role for Liquid Biopsies? Tumor Biol 39:1\u201315","journal-title":"Tumor Biol"},{"key":"6863_CR133","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semcancer.2017.08.010","volume":"52","author":"A Nicolini","year":"2018","unstructured":"Nicolini A, Ferrari P, Duffy MJ (2018) Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol 52:56\u201373","journal-title":"Semin Cancer Biol"},{"key":"6863_CR134","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10238-019-00563-w","volume":"19","author":"X Zhang","year":"2019","unstructured":"Zhang X, Ju S, Wang X, Cong H (2019) Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clin Exp Med 19:271\u2013279","journal-title":"Clin Exp Med"},{"key":"6863_CR135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2018.00009","volume":"5","author":"IB Hench","year":"2018","unstructured":"Hench IB, Hench J, Tolnay M (2018) Liquid biopsy in clinical management of breast, lung, and colorectal cancer. Front Med 5:1\u201324","journal-title":"Front Med"},{"key":"6863_CR136","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2017.04.007","volume":"44","author":"V Appierto","year":"2017","unstructured":"Appierto V, Di Cosimo S, Reduzzi C, Pala V, Cappelletti V, Daidone MG (2017) How to study and overcome tumor heterogeneity with circulating biomarkers: the breast cancer case. Semin Cancer Biol 44:106\u2013116","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"6863_CR137","first-page":"1","volume":"2018","author":"SW Fanning","year":"2018","unstructured":"Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buch-walter G, Houtman R, Toy W, Fowler CE, Han R et al (2018) The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018(7):1\u201326","journal-title":"Elife."},{"key":"6863_CR138","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD7-07","author":"V Kaklamani","year":"2020","unstructured":"Kaklamani V, Bardia A, Wilks S, Weise A, Richards D, Harb W, Os-borne C, Wesolowski R, Karuturi M, Conkling P et al (2020) Abstract PD7-07: final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2\u2212) advanced breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-PD7-07","journal-title":"Cancer Res"},{"key":"6863_CR139","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.2019.37.15_suppl.1056","volume":"37","author":"M Laine","year":"2019","unstructured":"Laine M, Fanning SW, Greene M, Chang YF, Phung L, Tan TT, Hii-pakka R, Komm B, Greene G (2019) Lasofoxifene as a potential treat- ment for ER plus metastatic breast cancer. J Clin Oncol 37:1056","journal-title":"J Clin Oncol"},{"key":"6863_CR140","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05575-9","author":"KJ Andreano","year":"2020","unstructured":"Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA et al (2020) G1T48, an oral selective estrogen receptor degrader, and the CDK4\/6 inhibitor leroci- clib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-020-05575-9","journal-title":"Breast Cancer Res Treat"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06863-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06863-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06863-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T14:36:35Z","timestamp":1641825395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06863-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6863"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06863-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"24 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have stated that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}